Back

What is the incidence of heart failure with preserved ejection fraction (HFpEF) versus heart failure with reduced ejection fraction (HFrEF) in breast cancer survivors compared to non-cancer controls?

19 June 2026 (15:30 - 16:15)
Organised by: Logo
Congress Presentation Part of: Heart failure and cancer therapy–related cardiac dysfunction: phenotypes, mechanisms and cardioprotection Diagnosis and Management of Cardiovascular Disease in Patients with Cancer Delegates Premium Access ESC Cardio-Oncology 2026 Council of Cardio-Oncology

About the speaker

Photo
Mr Adam Bolad

Zionsville (United States of America)

4 More presentations in this session

Presentation thumbnail
The cardiac phenotype of treatment naive patients with early breast cancer: a precursor to HFpEF?
Doctor I. Paterson (Ottawa, CA)
Abstract Slides
Presentation thumbnail
History of cancer and clinical outcomes in patients with recurrent acute heart failure; sub-analysis of the SAVIOR-L study
Professor Y. Fukumoto (Kurume, JP)
Abstract Slides
Presentation thumbnail
A circulating biotarget in breast-tumor-bearing mice suffering from chemotherapy-induced cardiac dysfunction
Doctor H. Nordin (Paris, FR)
Abstract Slides
Presentation thumbnail
GLP1 receptor agonism attenuates anthracycline and HER2 targeted therapy induced cardiac dysfunction and systemic inflammation in non-diabetic models
Doctor V. Quagliariello (Naples, IT)
Abstract Slides

Access the full session

Session thumbnail
Heart failure and cancer therapy–related cardiac dysfunction: phenotypes, mechanisms and cardioprotection

The Event

Event poster

ESC Cardio-Oncology 2026

19 June 2026 15:30 CET

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources